InvestorsHub Logo
Followers 13
Posts 1022
Boards Moderated 0
Alias Born 07/19/2013

Re: None

Friday, 01/04/2019 12:39:51 PM

Friday, January 04, 2019 12:39:51 PM

Post# of 13331
BioNTech Teams up With Sanofi to Target Solid Tumors in $91.5 Million Deal...

As part of the deal, the French pharma giant will invest about $91.5 million in equity in BioNTech, a privately-held company. The investment follows BioNTech’s 2018 decision to exercise one of the option rights under the 2015 agreement to co-develop and co-commercialize the immuno-oncology candidate. The two companies will work to develop an investigational therapy that includes an mRNA mixture encoding immunomodulatory cytokines that are injected directly into the tumor. Local administration of immunotherapies to the tumor microenvironment provides the opportunity to stimulate innate and adaptive immune responses against tumors, while potentially avoiding toxicities related to systemic administration of immuno-modulatory therapeutics.

https://www.biospace.com/article/biontech-teams-up-with-sanofi-to-target-solid-tumors-in-91-5-million-deal/

Looks like mRNA based vaccines for immunotherapies is the new trend in fighting cancers and infectious diseases.

Although this new comer is still in its infancy, I think there is great potential in this space. imo

GL
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent MRNA News